A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

Trial Profile

A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Mar 2018

At a glance

  • Drugs Bb 2121 (Primary)
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms KarMMa
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 21 Feb 2018 According to the bluebird bio media release, first patient was infused in this study.
    • 08 Jan 2018 According to a Celgene Corporation media release, the company expects to complete enrollment in the trial in 2018.
    • 07 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top